Sucralfate + Oxetacaine

Sucralfate + Oxetacaine Suspension occupies a clinically well-established position within the Suspensions and Gastroenterology segment of pharmaceutical therapy. Unlike plain antacids that simply neutralize acid, this combination works at the mucosal level — providing structural protection and local pain relief simultaneously.

Sucralfate is a basic aluminium salt of sucrose octasulfate. In the acidic environment of the stomach, it depolymerizes and forms a sticky, adhesive paste that binds selectively and tenaciously to exposed proteins on ulcerated or inflamed gastric and duodenal mucosa. This adherent gel creates a physical barrier against acid, pepsin, and bile salts — shielding the damaged tissue and allowing natural epithelial regeneration to proceed.

Oxetacaine (Oxethazaine) is a locally acting surface anesthetic with a distinct advantage over many other local anesthetics: it remains pharmacologically active in strongly acidic pH conditions. This makes it particularly suited to gastric formulations where the pH can drop well below 2.0 after food. It relieves the pain and burning associated with peptic ulcer disease, esophagitis, and gastritis by blocking sensory nerve transmission at the mucosal surface — without meaningful systemic absorption.

Together, they create a product with strong clinical logic and clear prescriber familiarity — making it a commercially solid choice for pharma marketing companies building gastroenterology portfolios. Saar Biotech manufactures this combination from our manufacturing facility in Baddi, Himachal Pradesh, under GMP-compliant liquid oral manufacturing protocols.

At Saar Biotech, we manufacture Sucralfate Oxetacaine Suspension using a proprietary controlled high-shear suspension manufacturing process that ensures the dense insoluble Sucralfate solid phase remains uniformly dispersed, consistently re-dispersible, and correctly viscous across every commercial batch.

• Suspension Uniformity Engineering: Sucralfate is a high-load, practically insoluble API that tends to settle rapidly in poorly formulated liquid bases. Our suspending agent system — selected specifically for the viscosity profile needed in a 100 ml and 200 ml gastroenterology suspension — ensures that every 10 ml dose drawn from any point in the bottle delivers the full 1000 mg Sucralfate and 20 mg Oxetacaine label claim, from the very first dose to the last.

• Viscosity Calibrated for Coating Action: A gastro-protective suspension must be viscous enough to coat the mucosal surface but fluid enough to be poured cleanly through a measuring cap. Our rheological targeting ensures the product supports the physical coating function of Sucralfate while remaining practical for the patient dosing experience — an important factor in maintaining brand reputation.

• Palatable Adult Flavour Systems: Raw Sucralfate and Oxetacaine carry a chalky, mineral taste profile that can deter patient compliance in repeat-use gastroenterology therapy. Our R&D team supports orange, mint, and sugar-free flavour systems designed specifically for this combination’s base chemistry, ensuring the finished suspension is commercially acceptable for the adult market.

• Premium Packaging Execution: From 320 GSM drip-off embossed cartons to metallic labels with silver leafing, measuring cups, brand-logo printed PP caps, and UV-coated carton finishes — Saar Biotech’s packaging capabilities allow B2B partners to create differentiated, pharmacy-shelf-ready Sucralfate brands that compete at presentation level, not just formulation level.

This manufacturing discipline ensures your Sucralfate Oxetacaine third-party brand consistently delivers barrier-protection performance and patient acceptability from the first batch to every repeat commercial run.

Sucralfate + Oxetacaine Suspension is manufactured and supplied by Saar Biotech for the following established clinical indications, making it a high-prescription gastroenterology product across GI-specialty and general medicine practice.

• Peptic Ulcer Disease (Gastric & Duodenal): The primary indication. Sucralfate’s adhesive barrier preferentially adheres to ulcer crater proteins, protecting the damaged mucosa from acid and enzymatic attack while natural healing occurs. It is approved for both active ulcer management and maintenance therapy.

• Chronic Gastritis & Acid-Related Dyspepsia: In cases of gastric mucosal inflammation, the combination delivers protective coating plus Oxetacaine’s localized numbing action, addressing the burning, heaviness, and post-meal discomfort that drives repeat prescriptions.

• Gastroesophageal Reflux Disease (GERD): Particularly useful where acid reflux causes esophageal mucosal contact injury and burning pain. Sucralfate forms a protective coat on irritated esophageal lining, while Oxetacaine reduces the sensory burning — together supporting symptom control as an adjunct to primary anti-reflux therapy.

• Esophagitis & Painful Dysphagia: The suspension format allows direct mucosal contact across the full upper GI tract — esophagus, stomach, and proximal duodenum — making it relevant for brands addressing acid-injury pain and difficulty swallowing as part of a comprehensive gastroenterology portfolio.

This formulation is a Schedule H prescription drug. Dispensing requires a valid medical prescription.

Dual-Mechanism Clinical Action

Sucralfate does not inhibit acid secretion or neutralize gastric acid. Its mechanism is purely local and structural. Under acidic conditions (pH < 4), Sucralfate undergoes polymerization to release aluminium hydroxide and a highly negative charged sucrose octasulfate complex. This complex binds electrostatically to positively charged proteins (albumin, fibrinogen) exposed at ulcer sites, creating an adhesive gel layer 2–6 mm thick that physically prevents acid and pepsin from reaching and damaging the underlying mucosal tissue. Sucralfate also stimulates prostaglandin synthesis, bicarbonate secretion, and mucous production — reinforcing the mucosal defense at multiple levels.

Oxetacaine acts as a surface-active local anesthetic that blocks voltage-gated sodium channels in sensory nerve endings of the gastric and esophageal mucosa. Its key clinical advantage is stability in strongly acidic environments — where conventional local anesthetics lose activity. This means Oxetacaine continues to provide meaningful pain relief in the stomach, where pH can fall well below 2.0 postprandially.

Manufacturing Integrity — Preserving Functional Activity

• Physical Stability of the Suspension Matrix: Sucralfate’s activity depends entirely on uniform dispersion and mucosal contact at the correct dose. Poor suspension formulation leads to sedimented, inactive API at the bottle’s base and under-dosed early doses at the top. Saar Biotech’s high-shear mixing process, combined with validated suspending agents and in-process particle distribution checks, eliminates this risk — ensuring every 10 ml dose is therapeutically identical.

• pH and Excipient Compatibility: The formulation base must remain compatible with both Sucralfate (which activates in acid) and Oxetacaine (which must retain physical dispersion and chemical stability throughout the 24-month shelf life). Our formulation team selects excipients that support both actives simultaneously, without compromising pourability, flavour masking, or shelf stability in Indian tropical warehouse conditions.

Sucralfate Oxetacaine Suspension’s B2B appeal is built around a straightforward, clinically credible story that prescribers and pharmacists understand intuitively — and that pharmaceutical marketing companies can position clearly without complex efficacy claims.

• Local Action = No Bioavailability Complexity: Sucralfate is minimally absorbed (less than 5% of administered dose). For brand owners, this supports a clean "protects your stomach, not your bloodstream" positioning — especially valuable for patients on multiple medications who are concerned about drug interactions.

• Immediate Symptomatic Relief Narrative: Oxetacaine’s local anesthetic action in the stomach delivers relief from burning within minutes of administration. This rapid-onset symptom control creates a strong patient experience that drives repeat prescription behavior — a key commercial metric for B2B brands building prescription loyalty in GI practice.

• Dose Presentation Advantage: The 10 ml per dose unit is easy for prescribers to communicate, pharmacists to counsel, and patients to measure with a standard measuring cap. The 100 ml pack offers a 10-day supply (at 4×/day), while the 200 ml pack covers a 20-day treatment course — giving brands two commercially distinct SKU options for different prescription durations.

• Sugar-Free Variant for Premium Positioning: Gastroenterology patients frequently include diabetics and metabolic syndrome patients who are advised to avoid sugar-containing liquids. A sugar-free Sucralfate Oxetacaine variant allows pharmaceutical marketing companies to tap into this segment with a specialized positioning that generic competition often lacks.

Saar Biotech operates a dedicated oral liquid and suspension manufacturing area in Baddi, Himachal Pradesh — specifically equipped for the high-load, high-viscosity suspension formats required for Sucralfate-based products.

• Facility: Segregated liquid oral manufacturing block with controlled mixing, automated filling, capping, labeling, and carton-packing workflows designed for gastroenterology suspensions.
• Capacity: Scalable from brand-entry pilot batches to high-volume commercial runs of 2,00,000+ units in 100 ml and 200 ml configurations.
• Quality Lab: In-house GLP-certified analytical laboratory performing assay, pH, viscosity, MLT, suspension uniformity, and fill-volume verification on every batch.
• Turnaround: New orders — 30 to 45 working days from artwork and documentation finalization. Repeat orders — 20 to 25 working days.
• Packaging: Full range — sticker label, metallic label, silver leafing, drip-off carton, UV finish, 320 GSM brand-embossed carton, measuring caps, company-logo printed PP caps.
• MOQ: Starting at 5,000–10,000 units per SKU; large-format 60×200 ml, 64×200 ml, and 72×200 ml configurations available for high-volume distributors.

1. Optimal Storage: Store Sucralfate Oxetacaine Suspension at room temperature below 30°C, in a cool, dry location away from direct heat sources and sunlight. Excessive heat can alter the suspension’s viscosity and compromise the flavour system.
2. No Freezing: Sub-zero temperatures will irreversibly disrupt the suspension matrix, causing hard caking of the Sucralfate solid phase that cannot be redispersed by shaking. Cold-chain logistics are not required, but freezing must be strictly avoided.
3. Shake Well Before Use: This instruction is critical and must appear prominently on the label and carton. Sucralfate particles will settle during storage — uniform shaking before every dose ensures the patient receives the full 1000 mg + 20 mg therapeutic dose.
4. Measuring Cap: Always include a calibrated measuring cap with 100 ml and 200 ml packs. It ensures accurate 10 ml dosing and gives the product a professional, clinically credible presentation at pharmacy level.

Every commercial batch of Sucralfate + Oxetacaine Suspension manufactured at Saar Biotech is quarantined until it passes a comprehensive analytical release protocol designed for oral suspension products:

• Assay (Label Claim Accuracy): Sucralfate 1000 mg and Oxetacaine 20 mg per 10 ml are confirmed against IP specifications using validated analytical methods — ensuring no batch reaches the market with sub-therapeutic or over-strength active content.
• Suspension Uniformity & Re-Dispersibility: Physical settling behavior is assessed at multiple time points; re-dispersibility after shaking is confirmed to meet defined specifications so the patient’s first and last dose are clinically equivalent.
• pH & Viscosity Testing: pH is mapped to confirm the formulation matrix remains within the stability window for both actives. Viscosity testing ensures the product maintains the correct mouthfeel, pourability, and coating consistency across the shelf life.
• Microbial Limit Testing (MLT): Oral liquid products used in repeat-dosing regimens require rigorous microbiological testing. Every batch is confirmed free of specified pathogens and within IP total microbial count limits.
• Fill Volume & Closure Integrity: Automated inline volume checks and post-filling closure torque tests ensure every 100 ml and 200 ml bottle contains the declared volume with a leak-proof, tamper-evident seal.
• Certificate of Analysis (COA): Issued with every B2B delivery. Additional batch documentation — including BMR references — can be provided per commercial agreement.

• Common Side Effects: Constipation is the most frequently reported adverse effect of Sucralfate-containing products. Dry mouth, mild nausea, gastric discomfort, and headache have been reported rarely. Most effects are mild and resolve without intervention.
• Renal Precaution: In patients with chronic kidney disease (moderate to severe), the aluminium component of Sucralfate can accumulate systemically with repeated use, potentially causing aluminium toxicity. Medical supervision is essential in this population.
• Drug Interaction Warning: Sucralfate reduces oral absorption of fluoroquinolones, tetracyclines, digoxin, phenytoin, ketoconazole, levothyroxine, theophylline, and warfarin. A minimum 2-hour administration gap is advised for all co-medications.
• Contraindications: Known hypersensitivity to Sucralfate, Oxetacaine, or any excipient in the formulation. Not recommended for paediatric use under 12 years of age without specific medical guidance.
• Healthcare professionals should review the complete prescribing information before recommending this product in pregnancy, lactation, elderly patients, or those on complex multi-drug regimens.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Sucralfate + Oxetacaine Oral Suspension, please use the B2B enquiry form below.